– CANADA, Dartmouth – IMV Inc. (NASDAQ: IMV | TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Kyle Kuvalanka to its Board of Directors effective April 1, 2021.
Mr. Kuvalanka brings over 20 years of experience as a senior leader in the biopharmaceutical industry with a successful track record in forming and negotiating strategic collaborations, leading financings, facilitating strategy development, as well as building and directing business and finance functions. Currently, Mr. Kuvalanka serves as CFO and COO at Goldfinch Bio, a kidney precision medicines company.
“We welcome Kyle to our Board at this important time for our company, as our lead candidate, maveropepimut-S, continues to advance in Phase 2 trials across multiple hematologic and solid tumor indications,” said CEO, Fred Ors. “As we broaden our pipeline of immunotherapy candidates, we are thrilled to be able to leverage Kyle’s expertise in developing corporate and financing strategies for high-growth companies. We look forward to his expert engagement and assistance in guiding our objectives to advance our lead immunotherapy toward potential registration and commercialization.”
Concurrent to Mr. Kuvalanka’s appointment, Wayne Pisano, who has served on IMV’s Board of Directors since October 2011, will be retiring from his role.
Board Chairman, Andy Sheldon commented: “We are exceptionally grateful for Wayne’s service and his significant contributions to our clinical pipeline during that time. On behalf of my fellow Board members and IMV’s management team, I would like to thank Wayne for his dedicated service to the company.”
About Kyle Kuvalanka
Prior to joining Goldfinch Bio, Mr. Kuvalanka advised private biopharmaceutical and portfolio companies of venture capital firms, including Third Rock Ventures, on their corporate and financial strategies and helped to build several investor syndicates. Previously, he served as COO and Principal Financial and Accounting Officer at Syros Pharmaceuticals (Nasdaq: SYRS) and Chief Business Officer and Principal Financial and Accounting Officer at Blueprint Medicines (Nasdaq: BPMC). In these roles, Mr. Kuvalanka helped to transition the companies from early-stage start-ups to publicly traded, clinical-stage organizations. In particular, he built the business and finance functions, led the execution of several financings, including the companies’ initial public offerings, and led the negotiations of the companies’ early strategic collaborations. Earlier in his career, Mr. Kuvalanka worked in roles of increasing responsibility over twelve years at Millennium: The Takeda Oncology Company, including as Vice President of Business Development and Corporate Strategy and a member of the company’s executive leadership team.
“IMV has a unique immunotherapy platform, fueled by its novel DPX delivery technology, which IMV is leveraging to build a multi-asset pipeline of medicines in oncology and other areas of high unmet medical need. IMV’s lead product candidate maveropepimut-S, which has demonstrated exciting data in diffuse large B cell lymphoma and ovarian cancer, is emblematic of the platform’s potential,” said Kyle Kuvalanka. “I am thrilled to join IMV’s Board and to work with Fred, the broader IMV team, and my fellow board members to support IMV’s future progress and ambitions on behalf of patients.”
He holds an MBA from the Wharton School of the University of Pennsylvania, and a BA with Honors from Wesleyan University.
About IMV
IMV Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer immunotherapies based on the Company’s proprietary delivery platform. This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects. IMV’s lead candidate, Maveropepimut-S, is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing Maveropepimut-S in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.
For more information: https://www.imv-inc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.